Phase 2 Lymphoma Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have been diagnosed with a specific type of lymphoma called CD20-positive Post-Transplant Lymphoproliferative Disorder (PTLD), confirmed by a tissue sample, including the polymorphic or monomorphic subtypes.
- People aged 15 or older.
- People who have measurable disease, meaning at least one affected lymph node measuring 1.5 cm or larger.
- People who have had a PET-CT scan (or a CT scan of the chest, abdomen, and pelvis with contrast dye) within the 28 days before joining the study.
- People who have been tested for hepatitis B virus (HBV) within 28 days before joining; people who carry HBV but have an undetectable viral load while on suppressive treatment may be eligible (confirm with trial site).
- People with a past hepatitis C virus (HCV) infection who have been fully treated and cured, or people with an active HCV infection who are currently being treated and have an undetectable viral load within 28 days before joining.
- People living with HIV, provided they are on effective HIV treatment and have had an undetectable viral load within the past 26 weeks, and have had a CD4 count checked within 28 days before joining.
- People whose heart, organ, and general physical functioning are considered suitable for the study treatments, as determined by their treating doctor.
- People who are able to give written informed consent, or whose legally authorised representative is able to consent on their behalf if the person has difficulty with this.
- Women of childbearing age who have a documented negative pregnancy blood test within 2 weeks of starting treatment.
- People who agree to use adequate contraception (such as hormonal or barrier methods, or abstinence) throughout the study.
- Women who agree not to breastfeed for the entire duration of the study.
- People who have not received chemotherapy for other conditions within the past 4 weeks (or 6 weeks for certain specific chemotherapy types), and who have recovered from any side effects of prior treatment.
- People who have not previously received more than a total dose of 250 mg/m² of the chemotherapy drug doxorubicin, or an equivalent amount of a similar drug.
Who may not be able to join:
- People who have already received chemotherapy treatment specifically for PTLD.
- People who have lymphoma that is known to have spread to the brain or spinal cord (central nervous system).
- People with active hepatitis B, defined as a viral load greater than 500 IU/mL within 28 days before joining.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Jennifer Amengual, MD, Columbia University
Phone: 212-342-5162
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Number of participants with Complete Response (CR) rate of 60% or higher
Can't join this trial?
Data last synced from ClinicalTrials.gov: 8 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.